Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Surbhi Jain

Why Buffett Is Splurging $10 Billion On OxyChem, Which Has Just $5 Billion In Revenue

Occidental Chemical Corporation,Plant.,Occidental

Warren Buffett's Berkshire Hathaway Inc (NYSE:BRK) (NYSE:BRK) isn't just buying a business — it's buying a cash machine with staying power. The conglomerate is reportedly in advanced talks to acquire Occidental Petroleum Corp's (NYSE:OXY) petrochemical unit, OxyChem, for around $10 billion, despite the company generating roughly $5 billion in annual revenue.

  • Track OXY stock here.

At first glance, it may seem steep, but a deeper look reveals why this deal fits perfectly with Buffett's playbook.

Stable, Essential Cash Flows

OxyChem produces critical chemicals such as chlorine, caustic soda, and PVC, used in water treatment, pharmaceuticals, and construction. These products are consistently in demand, providing the unit with predictable, recession-resistant revenue.

For Buffett, businesses with steady cash flows are worth paying a premium for — even if the top-line isn't eye-popping.

Read Also: Buffett’s Stealthy Stock Picks: Occidental Petroleum And The Oracle’s Quiet Wins

Healthy Margins And Long-Term Durability

Revenue alone doesn't tell the story. Petrochemical operations, such as OxyChem, often enjoy 20–30% EBITDA margins, resulting in a significant profit relative to sales. Occidental Petroleum’s overall EBITDA margin for 2024 was approximately 47.85%, implying OxyChem must also be generating decent margins.

Combined with a strong U.S. market position, this makes OxyChem a durable, high-quality business — precisely the type Buffett likes to hold for decades.

Strategic And Inflation Benefits

Beyond cash flows, OxyChem offers exposure to inflation-linked revenue, as chemical prices often adjust with commodity costs. There's also potential for operational efficiencies and long-term growth, which could enhance returns beyond the current valuation.

For Berkshire, this isn't a short-term play — it's a long-term bet on essential American industry.

Investor Takeaway

Paying $10 billion for $5 billion in revenue might raise eyebrows, but for Buffett, it's about stability, profitability, and strategic value. OxyChem represents a reliable, cash-generating asset that fits Berkshire Hathaway's formula: buy high-quality businesses, hold them for decades, and let the cash flow compound.

For investors, this deal serves as a reminder that revenue alone doesn't tell the whole story — quality, durability, and predictability can justify paying a premium.

Read Next:

Photo: Shutterstock

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.